Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data.

Kothare S, Kluger G, Sachdeo R, Williams B, Olhaye O, Perdomo C, Bibbiani F.

Seizure. 2017 Apr;47:25-33. doi: 10.1016/j.seizure.2017.02.008. Epub 2017 Feb 17. Review.

2.

Behcet's Disease: The Darker side !

Diwan A, Krishna K, Sachdeo R, Shimpi L.

J Assoc Physicians India. 2016 May;64(5):93-94.

PMID:
27735168
3.

A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development.

Sachdeo R, Partiot A, Biton V, Rosenfeld WE, Nohria V, Tompson D, DeRossett S, Porter RJ.

Int J Clin Pharmacol Ther. 2014 Jun;52(6):509-18. doi: 10.5414/CP202081.

PMID:
24755135
4.

Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial.

Brodie MJ, Rosenfeld WE, Vazquez B, Sachdeo R, Perdomo C, Mann A, Arroyo S.

Epilepsia. 2009 Aug;50(8):1899-909. doi: 10.1111/j.1528-1167.2009.02160.x. Epub 2009 Jun 1.

5.

Optimisation and data mining techniques for the screening of epileptic patients.

Fan YJ, Chaovalitwongse WA, Liu CC, Sachdeo RC, Iasemidis L, Pardalos P.

Int J Bioinform Res Appl. 2009;5(2):187-96.

PMID:
19324604
6.

Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.

Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S.

Neurology. 2008 May 20;70(21):1950-8. doi: 10.1212/01.wnl.0000303813.95800.0d. Epub 2008 Apr 9.

PMID:
18401024
7.

Monotherapy clinical trial design.

Sachdeo R.

Neurology. 2007 Dec 11;69(24 Suppl 3):S23-7. Review.

PMID:
18071154
8.

Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.

Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM; 205 Study Group.

Neurology. 2007 Apr 10;68(15):1197-204.

PMID:
17420403
9.

Improved quality of life in patients with partial seizures after conversion to oxcarbazepine monotherapy.

Sachdeo RC, Gates JR, Bazil CW, Barkley GL, Tatum W, D'Souza J, McCague K.

Epilepsy Behav. 2006 Nov;9(3):457-63. Epub 2006 Aug 24.

PMID:
16934534
10.
11.

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society.

Neurology. 2004 Apr 27;62(8):1261-73. Review.

PMID:
15111660
12.

Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society.

Neurology. 2004 Apr 27;62(8):1252-60. Review.

PMID:
15111659
13.

Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee; American Epilepsy Society Quality Standards Subcommittee.

Epilepsia. 2004 May;45(5):410-23. Review. Erratum in: Epilepsia. 2004 Nov;45(11):1299.

14.

Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee.

Epilepsia. 2004 May;45(5):401-9. Review.

15.

Caffeinated beverages and decreased seizure control.

Kaufman KR, Sachdeo RC.

Seizure. 2003 Oct;12(7):519-21.

16.
17.

Oxcarbazepine for Treatment of Partial Epilepsy: A Review and Recommendations for Clinical Use.

Schmidt D, Sachdeo R.

Epilepsy Behav. 2000 Dec;1(6):396-405.

PMID:
12737829
18.

Tiagabine in the Management of Postencephalitic Epilepsy and Impulse Control Disorder.

Kaufman KR, Kugler SL, Sachdeo RC.

Epilepsy Behav. 2002 Apr;3(2):190-194.

PMID:
12609422
19.

Effects of oxcarbazepine on sodium concentration and water handling.

Sachdeo RC, Wasserstein A, Mesenbrink PJ, D'Souza J.

Ann Neurol. 2002 May;51(5):613-20.

PMID:
12112108
20.

Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.

Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M.

Epilepsia. 2002 Jul;43(7):691-6. Erratum in: Epilepsia 2002 Oct;43(10):1273.

21.

Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures.

Sachdeo R, Beydoun A, Schachter S, Vazquez B, Schaul N, Mesenbrink P, Kramer L, D'Souza J.

Neurology. 2001 Sep 11;57(5):864-71.

PMID:
11552018
22.

Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view.

Schmidt D, Arroyo S, Baulac M, Dam M, Dulac O, Friis ML, Kälviäinen R, Krämer G, van Parys J, Pedersen B, Sachdeo R.

Acta Neurol Scand. 2001 Sep;104(3):167-70. Review.

PMID:
11551237
23.

Rapid initiation of gabapentin: a randomized, controlled trial.

Fisher RS, Sachdeo RC, Pellock J, Penovich PE, Magnus L, Bernstein P.

Neurology. 2001 Mar 27;56(6):743-8.

PMID:
11274308
24.

Challenging our past paradigm in the management of epilepsy.

Sachdeo R.

Neurology. 2000;55(11 Suppl 3):S1-4. Review.

PMID:
11147562
25.

Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial.

Beydoun A, Sachdeo RC, Rosenfeld WE, Krauss GL, Sessler N, Mesenbrink P, Kramer L, D'Souza J.

Neurology. 2000 Jun 27;54(12):2245-51.

PMID:
10881247
26.

Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group.

Glauser TA, Nigro M, Sachdeo R, Pasteris LA, Weinstein S, Abou-Khalil B, Frank LM, Grinspan A, Guarino T, Bettis D, Kerrigan J, Geoffroy G, Mandelbaum D, Jacobs T, Mesenbrink P, Kramer L, D'Souza J.

Neurology. 2000 Jun 27;54(12):2237-44.

PMID:
10881246
27.
28.
29.

A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.

Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G.

Neurology. 1999 Jun 10;52(9):1882-7.

PMID:
10371538
30.

Topiramate efficacy in infancy.

Kugler SL, Sachdeo RC.

Pediatr Neurol. 1998 Oct;19(4):320-2.

PMID:
9831007
31.

Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy.

Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu CO, Kamin M.

Neurology. 1998 Jun;50(6):1842-6.

PMID:
9633738
32.

Sensory sleep starts.

Sander HW, Geisse H, Quinto C, Sachdeo R, Chokroverty S.

J Neurol Neurosurg Psychiatry. 1998 May;64(5):690. No abstract available.

33.

Topiramate. Clinical profile in epilepsy.

Sachdeo RC.

Clin Pharmacokinet. 1998 May;34(5):335-46. Review.

PMID:
9592618
34.

Evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy.

Sachdeo RC, Narang-Sachdeo S, Montgomery PA, Shumaker RC, Perhach JL, Lyness WH, Rosenberg A.

J Clin Pharmacol. 1998 Feb;38(2):184-90.

PMID:
9549651
35.

Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy.

Sachdeo R, Narang-Sachdeo SK, Shumaker RC, Perhach JL, Lyness WH, Rosenberg A.

Epilepsia. 1997 Aug;38(8):887-92.

36.

Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group.

Sachdeo RC, Leroy RF, Krauss GL, Drake ME Jr, Green PM, Leppik IE, Shu VS, Ringham GL, Sommerville KW.

Arch Neurol. 1997 May;54(5):595-601.

PMID:
9152116
37.

Topiramate monotherapy for partial onset seizures.

Sachdeo RC, Reife RA, Lim P, Pledger G.

Epilepsia. 1997 Mar;38(3):294-300.

39.

Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy.

Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR.

Epilepsia. 1996 Aug;37(8):774-80.

PMID:
8764818
40.

Follow-up study of risk factors in progressive supranuclear palsy.

Golbe LI, Rubin RS, Cody RP, Belsh JM, Duvoisin RC, Grosmann C, Lepore FE, Mark MH, Sachdeo RC, Sage JI, Zimmerman TR Jr.

Neurology. 1996 Jul;47(1):148-54.

PMID:
8710069
41.

Felbamate.

Sachdeo RC.

Lancet. 1993 Jul 31;342(8866):300. No abstract available.

PMID:
8101318
42.

Felbamate monotherapy for partial-onset seizures: an active-control trial.

Faught E, Sachdeo RC, Remler MP, Chayasirisobhon S, Iragui-Madoz VJ, Ramsay RE, Sutula TP, Kanner A, Harner RN, Kuzniecky R, et al.

Neurology. 1993 Apr;43(4):688-92.

PMID:
8469323
43.

Felbamate monotherapy: controlled trial in patients with partial onset seizures.

Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S.

Ann Neurol. 1992 Sep;32(3):386-92.

PMID:
1416808
44.

Magnetic stimulation in the diagnosis of lumbosacral radiculopathy.

Chokroverty S, Sachdeo R, Dilullo J, Duvoisin RC.

J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):767-72.

45.

Generic versus branded carbamazepine.

Sachdeo RC, Belendiuk G.

Lancet. 1987 Jun 20;1(8547):1432. No abstract available.

PMID:
2884519
46.

Neurophysiologic study of olivopontocerebellar atrophy with or without glutamate dehydrogenase deficiency.

Chokroverty S, Duvoisin RC, Sachdeo R, Sage J, Lepore F, Nicklas W.

Neurology. 1985 May;35(5):652-9.

PMID:
3990965
47.

Pathology of olivopontocerebellar atrophy with glutamate dehydrogenase deficiency.

Chokroverty S, Khedekar R, Derby B, Sachdeo R, Yook C, Lepore F, Nicklas W, Duvoisin RC.

Neurology. 1984 Nov;34(11):1451-5.

PMID:
6493492
48.

Autonomic dysfunction and sleep apnea in olivopontocerebellar degeneration.

Chokroverty S, Sachdeo R, Masdeu J.

Arch Neurol. 1984 Sep;41(9):926-31.

PMID:
6383299

Supplemental Content

Loading ...
Support Center